Following is a cumulative list of Hoosier Cancer Research Network publications in quality of life/cancer control.

Manuscripts and Journal Articles

• Adra N, Albany C, Brames MJ, Case-Eads S, Johnson CS, Liu Z, Fausel CA, Breen T, Hanna NH, Hauke RJ, Picus J, Einhorn LH. Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumorsundergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study QL12-153. Support Care Center 2016 Feb 2 (epub ahead of print) PMID: 26838019
• Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH. Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group Study QL05-37. J Clin Oncol. 2012 Nov 10;30(32):3998-4003. doi: 10.1200/JCO.2011.39.5558. Epub 2012 Aug 2
• Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Hoosier Oncology Group Study QL05-37. Support Care Center 2007 Nov; 15(11): 1293-300.
• Rudolph M. Navari, Lawrence H. Einhorn, Patrick J. Loehrer Sr., Steven D. Passik, Jake Vinson, John McClean, Naveed Chowhan, Nasser Hanna, Cynthia Johnson:A Phase II Trial of Olanzapine, Dexamethasone and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Hoosier Oncology Group Study QL03-70. Support Care Cancer. 2007 Mar 21: 17375339 (P,S,E,B,D)
• Rudolph M. Navari, Lawrence H. Einhorn, Steven D. Passik, Patrick J. Loehrer Sr., Cynthia Johnson, M. L. Mayer, J. McClean, Jake Vinson, W. Pletcher; A Phase II Trial of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Hoosier Oncology Group Study QL01-26. Support Care Cancer. 2005 Jul;13(7):529-34. Epub 2005 Feb 8. PMID: 15700131
• MJ Fisch, JL Kristeller, S Passik, PJ Loehrer, LH Einhorn. Trial of Antidepressants for Mildly Depressed Cancer Patients Should Have Been Reported in a Manner Allowing Independent Evaluation of Investigators’ Claims. Journal of Clinical Oncology, Vol 22, No 4 (February 15), 2004: pp 749-758
• Passik SD. Navari RM. Jung SH. Nagy C. Vinson J. Kirsh KL. Loehrer P. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study QL00-4. Cancer Investigation. 22(3):383-8, 2004.
• Michael J. Fisch, Patrick J. Loehrer, Jean Kristeller, Steven Passik, Sin-Ho Jung, Jianzhao Shen, Matthew A. Arquette, Mary J. Brames, Lawrence H. Einhorn. Fluoxetine versus Placebo in Advanced Cancer Outpatients: A Double-Blinded Trial of the Hoosier Oncology Group QL97-1. J Clin Oncology Vol 21, Issue 10 (May), 2003: 1937-1943.
• Michael J. Fisch, Michael L. Titzer, Jean L. Kristeller, Jianzao Shen, Patrick J. Loehrer, Sin-Ho Jung, Steven D. Passik, and Lawrence H. Einhorn. Assessment of Quality of Life in Outpatients with Advanced Cancer: The Accuracy of Clinician Estimations and the Relevance of Spiritual Well-Being: A Hoosier Oncology Group Study. J Clin Oncology, Vol 21, Issue 14 (July), 2003: 2754-2759
• SD Passik, J Lundberg, KL Kirsh, D Theobald, K Donaghy, E Holtsclaw, M Cooper, W Dugan. A Pilot Exploration of the Antiemetic Activity of Olanzapine for the Relief of Nausea in Patients with Advanced Cancer and Pain. QL01-26 Journal of Pain and Symptom Management Vol. 23 No. 6 June 2002: 526-32

Abstracts, Posters, and Presentations

• Brames MJ, Case-Eads S, Hanna NH, Fausel CA, Breen T, Einhorn LH. Phase II study of fosaprepitant +5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: A Hoosier Cancer Research Network Study QL12-153. Accepted as an electronic publication at the ASCO Annual Meeting, May 29-June 2, 2015, Chicago IL. J Clin Oncol 33:5s, 2015 (suppl; abstr e20737). See abstract.
• Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Cancer Research Network QL12-153. Accepted for poster presentation at the MASCC/ ISOO Annual Meeting on Supportive Care in Cancer, June 25-27, 2015, Copenhagen Denmark.
• C. Albany, N.H. Hanna, J. Picus, R.J. Hauke, C.A. Fausel, Z. Liu, M.J. Brames, L.H. Einhorn. Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Oncology Group QL12-153. Accepted as a TiP poster at the genitourinary (non-prostate) cancer general poster session at the ASCO Annual Meeting, May 30 – June 3, 2014, Chicago IL. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4594)
• M.J. Brames, J. Picus, M. Yu, E. Johnston, B. Bottema, C. Williams, and L.H. Einhorn. Phase III double blind placebo controlled crossover study evaluating a 5HT3 antagonist + dexamethasone +/- aprepitant in germ cell tumor patients receiving 5 day cisplatin combination chemotherapy. A Hoosier Oncology Group study QL05-37. Accepted as an Oral Presentation (Abstract # A-327-0011-00199) to the 2011 International Symposium of the Multinational Association of Supportive Care in Cancer, June 23-25, Athens, Greece.
• M.J. Brames, J. Picus, M. Yu, E. Johnston, B. Bottema, C. Williams, and L.H. Einhorn.
  Phase III double blind placebo controlled crossover study evaluating a 5HT3 antagonist + dexamethasone +/- aprepitant in germ cell tumor patients receiving 5 day cisplatin combination chemotherapy. A Hoosier Oncology Group study QL05-37. Accepted as an Oral Presentation at the Oral Abstract Session (Abstract # 9013) at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL.
• M.J. Brames, E. Johnston, C.R. Nichols, J. Picus, D.J. Vaughn, C.A. Fausel, T.E. Breen, M. Yu, and L.H. Einhorn. Phase III double blind placebo controlled crossover study evaluating a 5HT3 antagonist + dexamethasone +/- aprepitant in germ cell tumor patients receiving 5 day cisplatin combination chemotherapy. A Hoosier Oncology Group study QL05-37. Accepted as a Poster Presentation at the International Symposium of the Multinational Association of Supportive Care in Cancer, June 24-26, 2010 Vancouver, Canada.
• R. M. Navari, L. H. Einhorn, P. J. Loehrer, S. D. Passik, J. Vinson, J. McClean, N. Chowhan, N. Hanna, C. Calley, M. Yu. A phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting (CINV) QL03-70. Accepted as a poster presentation at the ASCO Annual Meeting, June 2-6, 2006, Atlanta, GA. J Clin Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 8608
• R. M. Navari, L. H. Einhorn, P. J. Loehrer, S. D. Passik, J. Vinson, M. L. Mayer, W. Pletcher, J. McClean. A Phase II Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients Receiving Chemotherapy: Hoosier Oncology Group QL01-26. Presented as a poster discussion at the ASCO annual meeting June 5-8, 2004, New Orleans, LA. J Clin Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 8046
• Steve Passik, Patrick Loehrer, Rudolph Navari, Cindy Nagy, Jeanette Sawi, SinHo Jung; A Phase I Trial of Olanzapine (ZYPREXA) For the Prevention of Delayed Emesis in Cancer Patients Receiving Chemotherapy: A Hoosier Oncology Group Study QL00-4. Accepted as a poster presentation for ASCO annual meeting May 18-21, 2002, Orlando, FL.
• Michael L. Titzer, Michael Fisch, Jean L. Kristeller, Sin-Ho Jung, Patrick J. Loehrer, Lawrence H. Einhorn. Clinicians’ Assessment Of Quality Of Life (QoL) In Outpatients With Advanced Cancer: How Accurate Is Our Prediction? A Hoosier Oncology Group Study. Accepted as an oral presentation for ASCO annual meeting May 12-15, 2001, San Francisco, CA.
• Michael J. Fisch, Patrick J. Loehrer, Steven D. Passik, Jean L. Kristeller, Sin-Ho Jung, Lawrence H. Einhorn. Fluoxetine versus Placebo in Advanced Cancer Outpatients: A Placebo-Controlled, Double-Masked Trial of the Hoosier Oncology Group QL97-1. Accepted as an oral presentation for ASCO annual meeting May 12-15, 2001, San Francisco, CA.
• R. M. Navari, L. H. Einhorn, P. J. Loehrer, S. D. Passik, J. Vinson, J. McClean, N. Chowhan, N. Hanna, C. Calley, M. Yu. A Phase II Trial of Olanzapine (Zyprexa) and Palonosetron (Aloxi) for the Prevention of Chemotherapy Induced Nausea and Vomiting: Hoosier Oncology Group QL03-70. Accepted to the ASCO annual meeting June 2-6, 2006, Atlanta, Georgia